To tell or not to tell: The community wants to know about expensive anticancer drugs as a potential treatment option

Journal of Clinical Oncology

Volumn 27, Issue 34, 2009, Pages 5830-5837

  Mileshkin, Linda ^a   Schofield, Penelope E ^a   Jefford, Michael ^a   Agalianos, Emilia ^a   Levine, Michele ^a   Herschtal, Alan ^a   Savulescu, Julian ^a   Thomson, Jacqui Ann ^a   Zalcberg, John R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; COMMUNITY CARE; DEMOGRAPHY; DRUG COST; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; ADOLESCENT; AGED; AUSTRALIA; DOCTOR PATIENT RELATION; ECONOMICS; FEE; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; MIDDLE AGED; NEOPLASM; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AUSTRALIA; FEES, PHARMACEUTICAL; FEMALE; FINANCING, PERSONAL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PREFERENCE; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES; TRUTH DISCLOSURE; YOUNG ADULT;

EID: 73349096027     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.7793     Document Type: Article

References (42)

1. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
2. Lee TH, Emanuel EJ: Tier 4 drugs and the fraying of the social compact. N Engl J Med 359: 333-335, 2008
3. Thomson J, Schofield P, Mileshkin L, et al: Do oncologists discuss expensive anti-cancer drugs with their patients? Ann Oncol 17:702-708, 2006
4. Schrag D, Hanger M: Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey. J Clin Oncol 25:233-237, 2007
5. Cassileth BR, Zupkis RV, Sutton-Smith K, et al: Information and participation preferences among cancer patients. Ann Intern Med 92:832-836, 1980
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
7. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
8. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001 9. Dorofeev S, Grant P: Statistics for Real Life Sample Surveys: Non-Simple-Random Samples and Weighted Data. Cambridge, United Kingdom, Cambridge University Press, 2006
9. Kass GV: An exploratory technique for investigating large quantities of categorical data. J Appl Stat 29:119-127, 1980
10. Jefford M, Tattersall MH: Informing and involving cancer patients in their own care. Lancet Oncol 3:629-637, 2002
11. Jenkins V, Fallowfield L, Saul J: Information needs of patients with cancer: Results from a large study in UK cancer centres. Br J Cancer 84:48-51, 2001
12. Degner LF, Kristjanson LJ, Bowman D, et al: Information needs and decisional preferences in women with breast cancer. JAMA 277:1485-1492, 1997
13. Fallowfield L, Ford S, Lewis S: No news is not good news: Information preferences of patients with cancer. Psychooncology 4:197-202, 1995
14. Laine C, Davidoff F: Patient-centered medicine. A professional evolution. JAMA 275:152-156, 1996
15. Blanchard CG, Labrecque MS, Ruckdeschel JC, et al: Information and decision-making preferences of hospitalized adult cancer patients. Soc Sci Med 27:1139-1145, 1988
16. Butow PN, Dunn SM, Tattersall MH, et al: Patient participation in the cancer consultation: Evaluation of a question prompt sheet. Ann Oncol 5:199-204, 1994
17. Sutherland HJ, Llewellyn-Thomas HA, Lockwood GA, et al: Cancer patients: Their desire for information and participation in treatment decisions. J R Soc Med 82:260-263, 1989
18. Whelan TJ, Mohide EA, Willan AR, et al: The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. Cancer 80:1518-1524, 1997
19. Sowden AJ, Forbes C, Entwistle V, et al: Informing, communicating and sharing decisions with people who have cancer. Qual Health Care 10:193-196, 2001
20. Dimoska A, Girgis A, Hansen V, et al: Perceived difficulties in consulting with patients and families: A survey of Australian cancer specialists. Med J Aust 189:612-615, 2008
21. Pham HH, Alexander GC, O'Malley AS: Physician consideration of patients' out-of-pocket costs in making common clinical decisions. Arch Intern Med 167:663-668, 2007
22. Nadler E, Eckert B, Neumann PJ: Do oncologists believe new cancer drugs offer good value? Oncologist 11:90-95, 2006
23. Berry SR, Hubay S, Soibelman H, et al: The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: A qualitative study. BMC Health Serv Res 7:193, 2007
24. de Kort SJ, Kenny N, van Dijk P, et al: Cost issues in new disease-modifying treatments for advanced cancer: In-depth interviews with physicians. Eur J Cancer 43:1983-1989, 2007
25. Kaser E, Shaw J, Marven M: Communication about high-cost drugs in oncology: The patient view. Presented at the Annual Meeting of the Clinical Oncological Society of Australia, Sydney, Australia, November 18-20, 2008. Clin Oncol Soc Austr 2008 (abstr 19)
26. Willey VJ, Pollack MF, Lawless GD: Oncology health care and patient out-of-pocket costs trends in a commercially insured population. J Clin Oncol 26:337s, 2008 (suppl; abstr 6503)
27. McFarlane J, Riggins J, Smith TJ: SPIKE$: a six-step protocol for delivering bad news about the cost of medical care. J Clin Oncol 26:4200-4204, 2008
28. Jefford M, Mileshkin L, Schofield P, et al: Discussing expensive anticancer drugs. J Clin Oncol 27:476-477, 2009
29. Chao LW, Pagán JA, Soldo BJ: End-of-life medical treatment choices: Do survival chances and out-of-pocket costs matter? Med Decis Making 28: 511-523, 2008
30. Robotin MC, Penman AG: Integrating complementary therapies into mainstream cancer care: Which way forward? Med J Aust 185:377-379, 2006
31. Begbie SD, Kerestes ZL, Bell DR: Patterns of alternative medicine use by cancer patients. Med J Aust 165:545-548, 1996
32. Sinha G: Expensive cancer drugs with modest benefit ignite debate over solutions. J Natl Cancer Inst 100:1347-1349, 2008
33. Shmueli A: Survival vs. quality of life: A study of the Israeli public priorities in medical care. Soc Sci Med 49:297-302, 1999
34. Kim MK, Lee JL, Hyun MS, et al: Palliative chemotherapy preferences and factors that influence patient choice in incurable advanced cancer. Jpn J Clin Oncol 38:64-70, 2008
35. McQuellon RP, Muss HB, Hoffman SL, et al: Patient preferences for treatment of metastatic breast cancer: A study of women with early-stage breast cancer. J Clin Oncol 13:858-868, 1995
36. Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ 317:771-775, 1998
37. Yellen SB, Cella DF: Someone to live for: Social well-being, parenthood status, and decisionmaking in oncology. J Clin Oncol 13:1255-1264, 1995
38. Yellen SB, Cella DF, Leslie WT: Age and clinical decision making in oncology patients. J Natl Cancer Inst 86:1766-1770, 1994
39. Lloyd A, Penson D, Dewilde S, et al: Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 11:153-159, 2008
40. Matsuyama R, Reddy S, Smith TJ: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490-3496, 2006
41. Martin RC 2nd, McGuffin SA, Roetzer LM, et al: Method of presenting oncology treatment outcomes influences patient treatment decisionmaking in metastatic colorectal cancer. Ann Surg Oncol 13:86-95, 2006
42. Jefford M, Savulescu J, Thomson J, et al: Medical paternalism and expensive unsubsidised drugs. BMJ 331:1075-1077, 2005